Vacunas frente a la COVID-19: perfil de seguridad tras un año de seguimiento

  1. Alba María Fernández Varela
  2. Mónica Granero López
  3. Alejandro Rodríguez Rodríguez
  4. Isaura Rodríguez Penín
Revista:
Ars pharmaceutica

ISSN: 2340-9894,  0004-2927

Ano de publicación: 2024

Volume: 65

Número: 1

Páxinas: 6-12

Tipo: Artigo

DOI: 10.30827/ARS.V65I1.29180 DIALNET GOOGLE SCHOLAR lock_openAcceso aberto editor

Outras publicacións en: Ars pharmaceutica

Resumo

Introduction: After declaring the global pandemic due to the coronavirus COVID-19, measures were established to combat it, highlighting the existence of COVID-19 vaccines: two messenger RNA [mRNA] and two non-replicating viral vector [VVNR].Our objective was to contribute to expanding the safety profile of these vaccines through the detection and notification of adverse reactions (ARs) in a health area with 174,398 health cards during the year 2021. Method: Retrospective descriptive observational study carried out in a second level hospital. The sources of detection of the ADRs were: Coding System of the Center at the Discharge of the Admitted Patient [SIAC] and spontaneous notification. The data used were extracted from the electronic medical record and collected in a Microsoft Excell document. Results: Of the 654 ARs detected, 36 belonged to COVID-19 vaccines, 72 % being detected by spontaneous notification and 91.67 % being serious. They occurred in 29 patients (median age: 61 years; 51.72 % women), two of them with previous COVID-19 infection. 50 % of the ARs occurred after the second dose. They highlighted: deep vein thrombosis (DVT), pulmonary thromboembolism (PTE) and myopericarditis with mRNA vaccines; and vasculitis and myocarditis in VVNR. Conclusions: Although the available bibliography indicates that the frequency of serious ARs with these vaccines is usually rare, their follow-up is important. The high percentage of ADRs detected by spontaneous notification reflects the involvement of healthcare professionals to expanding the safety profile.

Referencias bibliográficas

  • Docea AO, Tsatsakis A, Albulescu D et al. A new threat from an old enemy: Re-emergence of coronavirus (Review). Int J Mol Med. 2020; 45: 1631-1643. Doi:10.3892/ijmm.2020.4555
  • Fathizadeh H, Maroufi P, Momen‑Heravi M et al. Protection and desinfection policies against SARS-CoV-2 (COVID-19). Infez Med. 2020; 28: 185-191.
  • Comirnaty, INN-Tozinameran, tozinameran/ritozinameran. [Ficha Técnica; Online]. Disponible en: https://cima.aemps.es/cima/pdfs/ft/1201528001/FT_1201528001.pdf [Consultada a 13 Noviembre 2022].
  • Vaxzevria® COVID-19 Vaccine (ChAdOx1-S [recombinant]). [Ficha Técnica; Online]. Disponible en: https://cima.aemps.es/cima/pdfs/ft/1211529001/FT_1211529001.pdf [Consultada a 13 Noviembre 2022].
  • JCOVDEN®, INN-Ad.26.COV2-S recombinant. [Ficha Técnica; Online]. Disponible en: https://cima.aemps.es/cima/pdfs/ft/1201525001/FT_1201525001.pdf [Consultada a 13 Noviembre 2022].
  • Spikevax, INN-elasomeran/imelasomeran/davesomeran. [Ficha Técnica; Online]. Disponible en: https://cima.aemps.es/cima/pdfs/ft/1201507001/FT_1201507001.pdf [Consultada a 13 Noviembre 2022].
  • Solsona EM. La farmacia hospitalaria: una gran aliada en la contribución al éxito de la campaña de vacunación frente a la COVID-19. OFIL ILAPHAR. 2021; 31(2):125-126.
  • WHO Coronavirus (COVID-19) Dashboard [Online]. Disponible en: https://covid19.who.int/ [Consultada a 13 Noviembre 2022].
  • Informes periódicos de farmacovigilancia de vacunas COVID-19 [Online] 2022. Disponible en: https://www.aemps.gob.es/la-aemps/ultima-informacion-de-la-aemps-acerca-del-covid%e2%80%9119/vacunas-contra-la-covid%e2%80%9119/farmacovigilancia-de-vacunas/informes-periodicos-de-farmacovigilancia-de-vacunas-covid-19/ [Consultada a 15 Diciembre 2022].
  • Graña C, Ghosn L, Evrenoglou T et al. Efficacy and safety of COVID-19 vaccines (Review). Cochrane Database of Systematic Reviews. 2022; 12. Doi: 10.1002/14651858.CD015477.
  • Seguridad de las vacunas contra el COVID-19. CDC. [Online]. Disponible en:https://espanol.cdc.gov/coronavirus/2019-ncov/vaccines/safety/safety-of-vaccines.html [Consultada a 17 Diciembre 2022].
  • Información para las notificaciones de sospechas de reacciones adversas a medicamentos por parte de profesionales sanitarios [Online]. Disponible en: https://www.aemps.gob.es/medicamentos-de-uso-humano/farmacovigilancia-de-medicamentos-de-uso-humano/notificacion-de-sospechas-de-reacciones-adversas-a-medicamentos-ram-de-uso-humano/notificasospechas-ram-profsanitarios/ [Consultada a 8 Abril 2023].
  • Gómez Marco JJ, Álvarez Pasquín MJ, Martín Martín S. Efectividad y seguridad de las vacunas para el SARS-CoV-2 actualmente disponibles. FMC. 2021; 28(8):442-51.
  • Esparza Olcina MJ, Fraile Astorga G, Juanes de Toledo B et al. Eficacia y seguridad de las vacunas contra el SARS-CoV-2. Rev Pediatr Aten Primaria. 2022; 24:e171-e182.
  • Actualización sobre el riesgo de miocarditis y pericarditis con las vacunas de ARNm frente a la COVID-19 [Online]. Disponible en:https://www.aemps.gob.es/informa/actualizacion-sobre-el-riesgo-de-miocarditis-y-pericarditis-con-las-vacunas-de-arnm-frente-a-la-covid-19/ [Consultada a 14 Diciembre 2022].
  • ZOE COVID Symptom Study. Vaccine after effects more common in those who already had COVID-19 [Online]. 2021. Disponible en: https://covid.joinzoe.com/post/vaccine-after-effects-more-common-in-those-who-already-had-covid. [Consultada a 1 Enero 2023]
  • Sharif N, Alzahrani KJ, Ahmed SN and Dey SK. Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis. Front Immunol. 2021; 12: 714170. Doi: 10.3389/fimmu.2021.714170.
  • Kantor IN, Lüthy IA, Ritacco V. Las variantes de SARS-CoV-2 y la llamada Resistencia a las vacunas. Medicina (Buenos Aires). 2021; 81:421- 426.
Fonte de datos: Dialnet